Advisors Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.38M Sell
3,085
-185
-6% -$142K 0.04% 547
2025
Q4
$2.52M Sell
3,270
-156
-5% -$106K 0.04% 523
2025
Q3
$1.93M Sell
3,426
-1,062
-24% -$600K 0.03% 610
2025
Q2
$2.36M Sell
4,488
-881
-16% -$492K 0.04% 530
2025
Q1
$3.41M Buy
5,369
+204
+4% +$140K 0.06% 413
2024
Q4
$3.68M Sell
5,165
-443
-8% -$372K 0.07% 382
2024
Q3
$5.9M Sell
5,608
-1,025
-15% -$1.14M 0.11% 240
2024
Q2
$6.97M Sell
6,633
-984
-13% -$954K 0.14% 185
2024
Q1
$7.33M Sell
7,617
-757
-9% -$720K 0.14% 181
2023
Q4
$7.35M Sell
8,374
-1,021
-11% -$841K 0.15% 163
2023
Q3
$7.73M Buy
9,395
+381
+4% +$299K 0.17% 137
2023
Q2
$6.48M Sell
9,014
-674
-7% -$520K 0.13% 174
2023
Q1
$7.96M Buy
9,688
+1,342
+16% +$1.01M 0.16% 140
2022
Q4
$6.02M Buy
8,346
+458
+6% +$338K 0.12% 184
2022
Q3
$5.43M Sell
7,888
-144
-2% -$90.6K 0.11% 199
2022
Q2
$4.75M Sell
8,032
-689
-8% -$448K 0.09% 249
2022
Q1
$6.09M Sell
8,721
-2,091
-19% -$1.32M 0.09% 228
2021
Q4
$6.83M Sell
10,812
-2,642
-20% -$1.62M 0.1% 208
2021
Q3
$8.14M Sell
13,454
-650
-5% -$404K 0.12% 166
2021
Q2
$7.88M Sell
14,104
-2,889
-17% -$1.46M 0.12% 169
2021
Q1
$8.04M Sell
16,993
-4,726
-22% -$2.3M 0.13% 159
2020
Q4
$10.5M Sell
21,719
-537
-2% -$290K 0.17% 111
2020
Q3
$12.5M Sell
22,256
-1,113
-5% -$675K 0.23% 79
2020
Q2
$14.6M Buy
23,369
+1,604
+7% +$910K 0.28% 66
2020
Q1
$10.6M Buy
21,765
+978
+5% +$403K 0.25% 83
2019
Q4
$7.8M Buy
20,787
+3,297
+19% +$1.11M 0.14% 171
2019
Q3
$4.85M Buy
17,490
+3,915
+29% +$1.16M 0.09% 259
2019
Q2
$4.25M Buy
13,575
+3,848
+40% +$1.28M 0.08% 296
2019
Q1
$3.99M Buy
9,727
+2,478
+34% +$1.02M 0.07% 320
2018
Q4
$2.71M Buy
7,249
+3,378
+87% +$1.24M 0.05% 406
2018
Q3
$1.56M Sell
3,871
-1,095
-22% -$417K 0.03% 687
2018
Q2
$1.71M Sell
4,966
-1,995
-29% -$624K 0.03% 646
2018
Q1
$2.23M Sell
6,961
-84
-1% -$29.2K 0.04% 567
2017
Q4
$2.65M Buy
7,045
+198
+3% +$80.2K 0.04% 531
2017
Q3
$3.06M Sell
6,847
-853
-11% -$406K 0.05% 477
2017
Q2
$3.78M Buy
7,700
+2,396
+45% +$1.05M 0.06% 412
2017
Q1
$2.06M Sell
5,304
-1,973
-27% -$731K 0.03% 620
2016
Q4
$2.67M Buy
7,277
+112
+2% +$42.6K 0.04% 541
2016
Q3
$2.88M Sell
7,165
-1,735
-19% -$696K 0.05% 516
2016
Q2
$3.11M Sell
8,900
-492
-5% -$189K 0.05% 515
2016
Q1
$3.38M Sell
9,392
-4,040
-30% -$1.66M 0.06% 480
2015
Q4
$7.29M Sell
13,432
-2,013
-13% -$1.09M 0.12% 252
2015
Q3
$7.18M Sell
15,445
-366
-2% -$197K 0.11% 260
2015
Q2
$8.07M Buy
15,811
+912
+6% +$445K 0.11% 251
2015
Q1
$6.73M Buy
14,899
+1,390
+10% +$589K 0.09% 283
2014
Q4
$5.54M Buy
13,509
+3,062
+29% +$1.2M 0.07% 324
2014
Q3
$3.77M Buy
10,447
+151
+1% +$50.6K 0.05% 418
2014
Q2
$2.91M Buy
10,296
+1,153
+13% +$342K 0.04% 477
2014
Q1
$2.75M Buy
9,143
+758
+9% +$234K 0.04% 467
2013
Q4
$2.31M Buy
8,385
+215
+3% +$61.8K 0.04% 472
2013
Q3
$2.56M Sell
8,170
-718
-8% -$189K 0.05% 440
2013
Q2
$2M Buy
+8,888
New +$2.07M 0.04% 459

Other funds holding REGN

Advisors Asset Management's REGN Position: Q1 2026 in Review

Advisors Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2026, selling an estimated $142K and leaving 3,085 shares worth $2.38M. The position accounts for 0.04% of the portfolio, ranked #547.

Advisors Asset Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.6M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Advisors Asset Management held 3,085 shares of Regeneron Pharmaceuticals worth $2.38M as of Q1 2026.
  • Advisors Asset Management sold 185 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $142K.
  • Regeneron Pharmaceuticals made up 0.04% of Advisors Asset Management's portfolio in Q1 2026, its #547 holding.
  • Advisors Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Advisors Asset Management's Regeneron Pharmaceuticals position peaked at $14.6M in Q2 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.